<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00788710</url>
  </required_header>
  <id_info>
    <org_study_id>0663-097</org_study_id>
    <secondary_id>2008_578</secondary_id>
    <nct_id>NCT00788710</nct_id>
  </id_info>
  <brief_title>A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Multicenter Trial to Study the Efficacy and Tolerability of MK0663/Etoricoxib in the Treatment of Pain After Abdominal Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of etoricoxib compared to
      placebo in the treatment of postoperative pain associated with total abdominal hysterectomy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Pain Intensity at Rest Over Days 1 to 3</measure>
    <time_frame>3 Days</time_frame>
    <description>Pain intensity at rest was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Total Daily Dose of Morphine Over Days 1 to 3</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Elicited Pain Upon Sitting Over Days 1 to 3</measure>
    <time_frame>3 days</time_frame>
    <description>Elicited pain upon sitting was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">430</enrollment>
  <condition>Acute Pain Following a Total Abdominal Hysterectomy</condition>
  <arm_group>
    <arm_group_label>Etoricoxib 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etoricoxib 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo- 3 tablets once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoricoxib (MK0663) 120 mg</intervention_name>
    <description>120 mg of etoricoxib (MK0663) for a total of 5 days</description>
    <arm_group_label>Etoricoxib 120 mg</arm_group_label>
    <other_name>Arcoxia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Placebo tablets once daily on Days 1-5. Total treatment is 5 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoricoxib (MK0663) 90 mg</intervention_name>
    <description>90 mg of etoricoxib (MK0663) for a total of 5 days</description>
    <arm_group_label>Etoricoxib 90 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years or older in generally good health who are scheduled to have a total
             hysterectomy and who are willing to limit alcohol consumption

        Exclusion Criteria:

          -  Patient is allergic to the study drug, other cyclooxygenase-2 (COX-2)
             inhibitors/nonsteroidal anti-inflammatory drugs (NSAIDS), ibuprofen, morphine, or
             oxycodone or has hypersensitivity to aspirin or other NSAIDS

          -  Patient has uncontrolled high blood pressure

          -  Patient has a history of drug and/or alcohol abuse within the last 5 years

          -  Patient has taken part in another investigational study within 4 weeks of the start of
             study

          -  Patient is breast-feeding

          -  Patient has an active ulcer or inflammatory bowel disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
    <country>Estonia</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2008</study_first_submitted>
  <study_first_submitted_qc>November 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2008</study_first_posted>
  <results_first_submitted>June 22, 2011</results_first_submitted>
  <results_first_submitted_qc>June 22, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 22, 2011</results_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoricoxib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Etoricoxib 120 mg</title>
          <description>Etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.</description>
        </group>
        <group group_id="P2">
          <title>Etoricoxib 90 mg</title>
          <description>Etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo - 3 tablets once daily on Days 1-5. Total treatment is 5 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="142"/>
                <participants group_id="P3" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etoricoxib 120 mg</title>
          <description>Etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.</description>
        </group>
        <group group_id="B2">
          <title>Etoricoxib 90 mg</title>
          <description>Etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo - 3 tablets once daily on Days 1-5. Total treatment is 5 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="144"/>
            <count group_id="B2" value="142"/>
            <count group_id="B3" value="144"/>
            <count group_id="B4" value="430"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.3" spread="6.9"/>
                    <measurement group_id="B2" value="47.0" spread="7.2"/>
                    <measurement group_id="B3" value="45.7" spread="7.0"/>
                    <measurement group_id="B4" value="46.3" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="144"/>
                    <measurement group_id="B4" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Pain Intensity at Rest Over Days 1 to 3</title>
        <description>Pain intensity at rest was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.</description>
        <time_frame>3 Days</time_frame>
        <population>Full analysis set population</population>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib 120 mg</title>
            <description>Etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Etoricoxib 90 mg</title>
            <description>Etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo - 3 tablets once daily on Days 1-5. Total treatment is 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Pain Intensity at Rest Over Days 1 to 3</title>
          <description>Pain intensity at rest was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.</description>
          <population>Full analysis set population</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="0.15"/>
                    <measurement group_id="O2" value="2.46" spread="0.15"/>
                    <measurement group_id="O3" value="3.26" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Total Daily Dose of Morphine Over Days 1 to 3</title>
        <time_frame>3 days</time_frame>
        <population>Full analysis set population</population>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib 120 mg</title>
            <description>Etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Etoricoxib 90 mg</title>
            <description>Etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo - 3 tablets once daily on Days 1-5. Total treatment is 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Total Daily Dose of Morphine Over Days 1 to 3</title>
          <population>Full analysis set population</population>
          <units>milligrams (mg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.37" spread="0.08"/>
                    <measurement group_id="O2" value="5.46" spread="0.08"/>
                    <measurement group_id="O3" value="7.75" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Elicited Pain Upon Sitting Over Days 1 to 3</title>
        <description>Elicited pain upon sitting was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.</description>
        <time_frame>3 days</time_frame>
        <population>Full analysis set population</population>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib 120 mg</title>
            <description>Etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Etoricoxib 90 mg</title>
            <description>Etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo - 3 tablets once daily on Days 1-5. Total treatment is 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Elicited Pain Upon Sitting Over Days 1 to 3</title>
          <description>Elicited pain upon sitting was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.</description>
          <population>Full analysis set population</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="0.17"/>
                    <measurement group_id="O2" value="3.80" spread="0.17"/>
                    <measurement group_id="O3" value="4.71" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Etoricoxib 120 mg</title>
          <description>Etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.</description>
        </group>
        <group group_id="E2">
          <title>Etoricoxib 90 mg</title>
          <description>Etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo - 3 tablets once daily on Days 1-5. Total treatment is 5 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Vaginal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Operative haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Fallopian tube cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="144"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="142"/>
                <counts group_id="E3" events="20" subjects_affected="18" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="142"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="41" subjects_affected="40" subjects_at_risk="144"/>
                <counts group_id="E2" events="35" subjects_affected="31" subjects_at_risk="142"/>
                <counts group_id="E3" events="43" subjects_affected="38" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="144"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="142"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E3" events="27" subjects_affected="24" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="144"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="142"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="144"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="142"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="142"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>11 participants were screened &amp; 10 participants were randomized at site 0028. An audit showed study medication dispensing logs were not kept. These 10 participants were invalidated and excluded from both efficacy &amp; safety analyses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

